BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29359185)

  • 21.
    Schäffler H; Breitrück A
    Front Microbiol; 2018; 9():646. PubMed ID: 29692762
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of fungi in C. difficile infection: An underappreciated transkingdom interaction.
    Stewart D; Romo JA; Lamendella R; Kumamoto CA
    Fungal Genet Biol; 2019 Aug; 129():1-6. PubMed ID: 30978391
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
    Lancaster JW; Matthews SJ
    Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gut metabolites predict Clostridioides difficile recurrence.
    Dawkins JJ; Allegretti JR; Gibson TE; McClure E; Delaney M; Bry L; Gerber GK
    Microbiome; 2022 Jun; 10(1):87. PubMed ID: 35681218
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences of the Fecal Microflora With Clostridium difficile Therapies.
    Louie TJ; Byrne B; Emery J; Ward L; Krulicki W; Nguyen D; Wu K; Cannon K
    Clin Infect Dis; 2015 May; 60 Suppl 2():S91-7. PubMed ID: 25922407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization.
    Zhang L; Dong D; Jiang C; Li Z; Wang X; Peng Y
    Anaerobe; 2015 Aug; 34():1-7. PubMed ID: 25817005
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors and intestinal microbiota: Clostridioides difficile infection in patients receiving enteral nutrition at Intensive Care Units.
    Wang D; Dong D; Wang C; Cui Y; Jiang C; Ni Q; Su T; Wang G; Mao E; Peng Y
    Crit Care; 2020 Jul; 24(1):426. PubMed ID: 32660525
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
    Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
    J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France.
    Watt M; Dinh A; Le Monnier A; Tilleul P
    J Med Econ; 2017 Jul; 20(7):678-686. PubMed ID: 28299963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era.
    Polage CR; Gyorke CE; Kennedy MA; Leslie JL; Chin DL; Wang S; Nguyen HH; Huang B; Tang YW; Lee LW; Kim K; Taylor S; Romano PS; Panacek EA; Goodell PB; Solnick JV; Cohen SH
    JAMA Intern Med; 2015 Nov; 175(11):1792-801. PubMed ID: 26348734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection.
    Miller M
    Expert Opin Pharmacother; 2010 Jun; 11(9):1569-78. PubMed ID: 20446864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
    Webb BJ; Brunner A; Ford CD; Gazdik MA; Petersen FB; Hoda D
    Transpl Infect Dis; 2016 Aug; 18(4):628-33. PubMed ID: 27214585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clostridium difficile colitis: review of the therapeutic approach.
    Joseph J; Singhal S; Patel GM; Anand S
    Am J Ther; 2014; 21(5):385-94. PubMed ID: 22990077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized clinical trial to evaluate the effect of fecal microbiota transplant for initial Clostridium difficile infection in intestinal microbiome.
    Camacho-Ortiz A; Gutiérrez-Delgado EM; Garcia-Mazcorro JF; Mendoza-Olazarán S; Martínez-Meléndez A; Palau-Davila L; Baines SD; Maldonado-Garza H; Garza-González E
    PLoS One; 2017; 12(12):e0189768. PubMed ID: 29261736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Diagnostic Algorithm for the Detection of Clostridium difficile-Associated Diarrhea.
    Yoldaş Ö; Altındiş M; Cufalı D; Aşık G; Keşli R
    Balkan Med J; 2016 Jan; 33(1):80-6. PubMed ID: 26966622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clostridium difficile infection: a review of current and emerging therapies.
    Ofosu A
    Ann Gastroenterol; 2016; 29(2):147-54. PubMed ID: 27065726
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Chen See JR; Leister J; Wright JR; Kruse PI; Khedekar MV; Besch CE; Kumamoto CA; Madden GR; Stewart DB; Lamendella R
    Front Microbiol; 2024; 15():1398018. PubMed ID: 38680911
    [No Abstract]   [Full Text] [Related]  

  • 40. Toward an understanding of changes in diversity associated with fecal microbiome transplantation based on 16S rRNA gene deep sequencing.
    Shahinas D; Silverman M; Sittler T; Chiu C; Kim P; Allen-Vercoe E; Weese S; Wong A; Low DE; Pillai DR
    mBio; 2012 Oct; 3(5):. PubMed ID: 23093385
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.